Navigation Links
Abraxis BioScience Presents Results from Pre-Clinical Study That,Demonstrates nab-Rapamycin's Robust Antitumor Properties and,Ability to Target Intracellular Sites Such as the mTOR Pathway

d other biological pathways, as well as for the development of new therapeutic candidates such as nab-docetaxel (ABI-008) and the HSP90 inhibitor nab-17-AAG (ABI 010), among others.

About nab(TM) Technology Platform

Developed by Abraxis BioScience, nanoparticle albumin-bound (nab(TM)) tumor-targeting technology harnesses the unique natural properties of the human protein albumin, to transport and deliver therapeutic agents to the site of disease. The binding of albumin to the anticancer agent creates nanometer-sized particles, which are approximately 1/100th the size of a single red blood cell. These nab particles are readily incorporated into the body's own transport processes and are able to exploit the tumors' attraction to albumin, enabling the delivery of higher concentrations of the active drug to the target site. This may lead to an increase in the drug's antitumor effect and the potential for an effective response. In addition, nab technology offers the ability to improve a drug's solubility by avoiding the need for toxic chemicals, such as solvents, in the administration process, thus potentially improving safety through the elimination of solvent-related side effects.

Abraxis BioScience received approval from the U.S. Food and Drug Administration for ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease in 2005, its first product developed using the nab technology. Studies are ongoing to evaluate several other therapeutic candidates that employ the nab technology including nab-docetaxel (ABI-008), nab-rapamycin mTOR inhibitor (ABI 009), and nab-17AAG HSP90 inhibitor (ABI 010), among others.

About Abraxis BioScience, Inc.

Abraxis BioScience, Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company develops, manufactures
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway
2. Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
9. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
10. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
11. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation

Post Your Comments:
(Date:11/30/2009)...MT. LAUREL, N.J., Nov. 30 /PRNewswire-FirstCall/...ovider of technology-enabled clinical documentatio...at the Radiological Society of North America (RSNA... Radiology, the product leverages SpeechQ(TM), the...n application used by thousands of radiologists. ...
(Date:11/30/2009)... , NEW YORK, Nov. 30 Reportlin...t is available in its catalogue: ,, Diabetes D...ttp://www.reportlinker.com/p0164347/Diabetes-Diagn...Diabetes Diagnosis market is driven by a steady in...etes, both in the developed and developing parts o...
(Date:11/30/2009)...AST ALTON, Ill., Nov. 30 The Simmo...tee dedicated to representing thousands of women t...n), the popular birth control pill manufactured an.... Judicial Panel on Multidistrict Litigation has o...ol pill lawsuits be consolidated and centralized f...
Breaking Medicine Technology:MedQuist Features SpeechQ VTB for Radiology Solution at RSNA Convention 2Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 2Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 3Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 4Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 5Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 6Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 7Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 8Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 9Simmons Firm's Partner Trent Miracle Chosen to Help Lead National Litigation Against Bayer 2Major Firms Eyeing CBMS Development of New Glaucoma Treatment 50916 1Major Firms Eyeing CBMS Development of New Glaucoma Treatment 50916 2Burrill 26 Company Invests in Taiwan Liposome Company 12918 1Burrill 26 Company Invests in Taiwan Liposome Company 12918 2Burrill 26 Company Invests in Taiwan Liposome Company 12918 3Influenza monitoring by the US military 50914 1Influenza monitoring by the US military 50914 2
...NCETON, N.J., Dec. 11 Pharmasset, Inc.,(Nasdaq: ...ommitted to,discovering, developing and commercial...ted financial results for the fiscal year ended Se... held $63.6 million in cash and cash,equivalents a... and 2008 Highlights , Clevudine , Dur...
... VEGAS, Dec. 11 CardioVascular BioTherapeutics, I...t two additional hospitals in the United States op... clinical trial for the treatment of severe corona...Institute Foundation in Minneapolis MN, and Prince... , Mercy Hospital Fairfield (Ohio) and The Chri...
Other Medicine Technology:Pharmasset Reports Fiscal Year End 2008 Financial Results 2Pharmasset Reports Fiscal Year End 2008 Financial Results 3Pharmasset Reports Fiscal Year End 2008 Financial Results 4Pharmasset Reports Fiscal Year End 2008 Financial Results 5Pharmasset Reports Fiscal Year End 2008 Financial Results 6Pharmasset Reports Fiscal Year End 2008 Financial Results 7Pharmasset Reports Fiscal Year End 2008 Financial Results 8Pharmasset Reports Fiscal Year End 2008 Financial Results 9CVBT Opens Two Additional Sites for Patient Enrollment for Phase II Heart Trial 2
(Date:11/30/2009)...nguage, social skills improve with specially desig.... 30 (HealthDay News) -- A special, intensive earl...cceeded in boosting IQ along with children,s langu...en done in this fashion, many children are able to...ne Dawson, lead author of the study, published onl...
(Date:11/30/2009)..., , SHORT HILLS, N.J., Nov. 30 /PRNewswire/ -...h Technologies, Inc. and OmniActive Health Technol...e settlement of their dispute. The parties agree t...ent") titled "Process for Isolation, Purification ...rigold Oleoresin and Uses Thereof" and the reissue...
(Date:11/30/2009)..., , DEL MAR, Calif., Nov. 30 /PRNewswire-...ation (Pink Sheets: ADHC) is pleased to announce t...ependent director to the Company,s Board of Direct... over a 40 year period starting at the Chemical Ba...rtner of Harris, Bretall & McEldowney, San Fra...
(Date:11/30/2009)..., , PHILADELPHI.../ -- , - Exclusive Updates From Elsevier,...e Reform and ARRA Momentum , Elsevier, a ...n as well,as web-based and electronic health recor...w online resource center for American Recovery and...
(Date:11/30/2009)...The U.S. Centers for Disease Control and Preventio...e United States are infected with HIV/AIDS. New re...that many of those infected are minorities and do ... for a national strategy to facilitate education a...opulations. , The research, which analyzed 90,00...
Breaking Medicine News(10 mins):Health News:Working Intensely Early on May Help Autistic Kids 2Health News:Working Intensely Early on May Help Autistic Kids 3Health News:Working Intensely Early on May Help Autistic Kids 4Health News:American Diversified Holdings Corporation Announces Appointment of Independent Director to the Board of the Company 2Health News:Elsevier Launches New Online ARRA Resource Center and Clinical Decision Support Blog 2Health News:Elsevier Launches New Online ARRA Resource Center and Clinical Decision Support Blog 3Health News:Elsevier Launches New Online ARRA Resource Center and Clinical Decision Support Blog 4Health News:Research highlights need for national HIV strategy 2
...reliminary investigation it has been found that if...y women are more susceptible to liver disease late...in Finland on 21,008 women and found the above men...d in the April 2006 issue of Hepatology, the offic...
...shtra state Health Directorate officials have conf...uniya', a mosquito-transmitted viral fever in abou...le who showed the symptoms of the disease have bee..., showing positive results for the fever. "Several...
...en who drink juice do not face the risk of obesity...ned about the effects of the juice in children’s d...us ages and had come to this conclusion. // ...ed 12-18 years had significantly lower BMIs than t...
...chers at the Mayo Clinic have discovered the epine... syndrome with an accuracy of about 75%. // Th...rt rhythm disorder occurring right from birth and ...uch people with the disease. If untreated, 50...
...olera epidemic has swept through Angola covering t...a Norte. Since the declaration of the cholera out... has risen to 2,026 with a death toll of 48. // ... Dunem. The National Laboratory of Public Heal...
...nd's new world-class children's hospital has now p...ated there. // With growing Concern being repeated...towards adult services as soon as they turn 13. NH... to meet young people's needs. The ideas are ...
Other Medicine News:Health News:Intrahepatic cholestasis during pregnancy predisposes to later liver disease 2
...e Osmometer is designed to automate testing for la...samples. By using the industry-preferred method of...nation of total concentration, combined with high,...odel 3900 will provide your laboratory optimal eff...
...Osmometer is an automated, single-sample osmometer... is ideally suited for clinical and industrial app...l 3320 employs the industry preferred freezing-poi... and dependable throughout fifty years of worldwid...
... Osmometer provides extremely accurate osmolality ... settings. These results are obtained by using the...etermines total concentration. Only the model 2020...ted sample handling, and flexible reporting option...
...smometer requires only a 20L sample size, which pr... seconds. For convenience, the fully accessible pr...s not only your most reliable option, it's the eas...sable sample tube, then place the tube into the te...
Medicine Products: